Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study

Griffin, Leanne; Hammond, Christopher J.; Liu, Dachao; Rademaker, Alfred; Kiley, Jessica

doi:10.1016/j.contraception.2017.02.020

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study findings suggest moderate interference in normal weight [169] and overweight/obese women's ability to lose gestational weight after implant insertion [174].…”

Section: Post-partum Implant Placementmentioning

confidence: 85%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved for reversible contraception. The etonogestrel (ENG) single rod dispositive has been widely employed in clinical practice, since it is a highly effective and safe contraceptive method. Abnormal menstrual bleeding is a common ENG side effect, representing the main reason for its premature discontinuation. Emerging evidence demonstrated that it is possible to extend the use of the ENG implant beyond the three-year period for which it is approved. The ENG implant could be an effective and discrete alternative to the IUD in young girls, such as post-partum/post-abortion. Implants should be inserted by trained skilled clinicians who previously provide adequate counselling about their contraceptive effect, benefits, and any possible adverse events. More studies are needed to validate the extended use of the ENG implant for up to 5 years.

show abstract

“…Study findings suggest moderate interference in normal weight [169] and overweight/obese women's ability to lose gestational weight after implant insertion [174].…”

Section: Post-partum Implant Placementmentioning

confidence: 85%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The acceptance of ENG‐implant in the postpartum period, before discharge, is still little being explored 13 . A study involving 127 women found an acceptance rate of 42% for ENG‐implant versus non‐hormonal methods, 14 a rate lower than the one we found, but the authors included an overweight or obese older population.…”

Section: Discussionmentioning

confidence: 55%

Acceptability of ENG‐releasing subdermal implants among postpartum Brazilian young women during the COVID‐19 pandemic

Barbieri

Herculano

Silva

et al. 2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To evaluate etonogestrel (ENG)‐implant acceptance during the immediate postnatal period among adolescents and young women during the COVID‐19 pandemic, and to compare variables according to choice and discuss possible implications of this measure during the pandemic period. Methods A cross‐sectional study was designed. All women aged up to 24 years, who delivered between April 25, 2020, and June 24, 2020, at Women's Hospital, University of Campinas, São Paulo, Brazil were considered. The ENG‐implant or other contraceptive methods were offered prior to hospital discharge. The participants were split into two groups: (1) those who chose the ENG‐implant and (2) those that refused the implant. Descriptive, bivariate, and multivariate analyses were performed. Results 151 women were included, with 76.2% selecting the ENG‐implant. The average age was 19.5 years; 73.2% of pregnancies were unplanned, 32.5% already had a previous pregnancy, 74% were single, and 75.5% were not in full time education. Further, 70.5% had previously used contraceptives, with 89.1% unsatisfied with their previous method that opted for the ENG‐implant (P = 0.07). Conclusion Offering the ENG‐implant to youths during the immediate postnatal period is evidence‐based care, and contraceptive provision is an essential health promotion tool, even during a pandemic. Thinking quickly about public policies in times of crisis is important to guarantee sexual and reproductive rights.

show abstract

“…Insertion of the implant is simple and safe, however adequate training is required. 16,17 Assessment of risk/benefit, as well as other factors regarding the impact of hormonal contraception while breastfeeding must be considered. The WHO eligibility criteria show that the risk of using Depot Medroxyprogesterone Acetate in women less than 6 weeks postpartum outweighs the benefits (category 3).…”

mentioning

confidence: 99%